Cosciens Biopharma Financials
Cosciens Biopharma (CSCI) reported $7.5M in revenue for fiscal year 2025, down 21.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cash burn still defines the business: losses narrowed, but balance-sheet capacity kept shrinking faster than revenue could support.
The headline improvement in net loss to-$10.4M from the prior year's deeper loss did not rebuild the balance sheet; equity still shrank to$3.8M . That leaves a liquidity-versus-solvency split: the current ratio was 3.2x, yet operating cash flow was-$8.5M .
This is a cash-consuming operation, not just an accounting-loss story: free cash flow was
The balance sheet has shifted from cash-rich and lightly levered to asset-thin: cash fell from
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Cosciens Biopharma's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Cosciens Biopharma, and counted as zero in the overall score.
Cosciens Biopharma passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Cosciens Biopharma reported a net loss of $10.4M while operations used $8.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Cosciens Biopharma generated $7.5M in revenue in fiscal year 2025. This represents a decrease of 21.8% from the prior year.
Cosciens Biopharma reported -$10.4M in net income in fiscal year 2025. This represents an increase of 32.3% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Cosciens Biopharma recorded an outflow of $9.2M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 41.6% from the prior year.
Cosciens Biopharma held $7.3M in cash against $1.9M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Cosciens Biopharma's ROE was -269.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 153.3 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Cosciens Biopharma invested $706K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 39.2% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
CSCI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.5M-21.8% | $9.6M+34.2% | $7.1M-51.0% | $14.6M+177.0% | $5.3M+44.0% | $3.7M+586.5% | $532K-98.0% | $26.9M+2812.4% | $923K+1.3% | $911K+67.2% | $545K |
| Interest Expense | $136K+56.3% | $87K-8.4% | $95K+2275.0% | $4K-42.9% | $7K-63.2% | $19K-71.2% | $66K-94.5% | $1.2M-57.2% | $2.8M-38.0% | $4.5M+129.4% | -$15.3M |
| Income Tax | $10K-88.1% | $84K+109.5% | -$885K-181.9% | $1.1M+1090.8% | -$109K-127.6% | $395K+310.1% | -$188K-103.4% | $5.5M+256.7% | -$3.5M | $0 | $0 |
| Net Income | -$10.4M+32.3% | -$15.3M-339.3% | -$3.5M-201.1% | $3.4M+141.2% | -$8.4M-63.5% | -$5.1M+15.3% | -$6.0M-244.3% | $4.2M+124.9% | -$16.8M+32.7% | -$25.0M+50.2% | -$50.1M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EPS (Diluted).
CSCI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $21.4M-38.9% | $35.1M+47.7% | $23.7M-14.7% | $27.8M-65.2% | $80.1M+116.5% | $37.0M+85.2% | $20.0M-20.1% | $25.0M+12.7% | $22.2M-29.9% | $31.7M | N/A |
| Current Assets | $11.5M-52.0% | $24.0M+112.8% | $11.3M | N/A | $70.8M+156.5% | $27.6M+153.1% | $10.9M-32.9% | $16.3M+73.3% | $9.4M-58.8% | $22.7M | N/A |
| Cash & Equivalents | $7.3M-55.4% | $16.4M+145.5% | $6.7M-34.5% | $10.2M+65.5% | $6.2M-74.6% | $24.3M+209.7% | $7.8M-46.0% | $14.5M+86.5% | $7.8M-64.6% | $22.0M-46.9% | $41.5M |
| Inventory | $1.3M-51.4% | $2.7M-32.9% | $4.0M+1650.7% | $229K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $1.3M-46.5% | $2.4M+712.8% | $290K-60.4% | $732K-44.3% | $1.3M-21.8% | $1.7M+155.5% | $658K+123.8% | $294K+33.0% | $221K-39.5% | $365K | N/A |
| Goodwill | N/A | N/A | N/A | N/A | $8.1M-7.8% | $8.8M+9.5% | $8.1M-1.9% | $8.2M-4.7% | $8.6M+14.0% | $7.6M-3.6% | $7.8M |
| Total Liabilities | $17.6M-19.7% | $21.9M+708.5% | $2.7M-32.6% | $4.0M-85.2% | $27.1M+14.0% | $23.8M+6.0% | $22.4M-2.9% | $23.1M-7.5% | $25.0M-1.8% | $25.4M | N/A |
| Current Liabilities | $3.6M-50.0% | $7.2M+450.9% | $1.3M | N/A | $7.8M+63.8% | $4.7M-16.2% | $5.7M+1.1% | $5.6M-3.0% | $5.8M+37.2% | $4.2M | N/A |
| Long-Term Debt | $1.9M-5.1% | $2.0M+45.7% | $1.4M+2052.3% | $65K+109.7% | $31K-36.7% | $49K-80.8% | $255K | N/A | N/A | N/A | N/A |
| Total Equity | $3.8M-70.8% | $13.2M-37.4% | $21.0M-11.7% | $23.8M-55.0% | $53.0M+301.1% | $13.2M+636.4% | -$2.5M-229.2% | $1.9M+168.5% | -$2.8M-144.8% | $6.2M-71.3% | $21.6M |
| Retained Earnings | -$20.5M-69.3% | -$12.1M-378.0% | $4.4M+101.2% | -$352.1M-5.2% | -$334.6M-3.7% | -$322.7M-1.8% | -$316.9M-2.3% | -$309.8M+1.4% | -$314.2M-5.4% | -$298.1M | N/A |
CSCI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$8.5M+41.8% | -$14.6M-464.2% | -$2.6M-149.4% | $5.2M+160.9% | -$8.6M-107.8% | -$4.1M+61.5% | -$10.7M-257.1% | $6.8M+129.8% | -$22.9M+21.0% | -$29.0M+14.3% | -$33.8M |
| Capital Expenditures | $706K-39.2% | $1.2M+60.8% | $722K+137.5% | $304K+913.3% | $30K | N/A | N/A | $9K+125.0% | $4K-93.9% | $66K+153.8% | $26K |
| Free Cash Flow | -$9.2M+41.6% | -$15.7M-376.1% | -$3.3M-167.1% | $4.9M+157.2% | -$8.6M | N/A | N/A | $6.8M+129.7% | -$22.9M+21.2% | -$29.1M+14.2% | -$33.9M |
| Investing Cash Flow | -$458K-101.8% | $25.1M+3536.0% | -$730K-140.1% | -$304K+53.8% | -$658K-1275.0% | $56K+12.0% | $50K+242.9% | -$35K-111.4% | $307K+197.8% | -$314K-134.4% | $913K |
| Financing Cash Flow | -$407K+30.8% | -$588K-64.7% | -$357K-33.7% | -$267K-100.5% | $51.0M+149.4% | $20.5M+425.8% | $3.9M | $0-100.0% | $8.0M-19.1% | $9.9M-75.7% | $40.8M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
CSCI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | -138.1% | -159.7% | -48.8%-72.5pp | 23.7% | -159.1% | -140.1% | -1135.7% | 15.6% | -1819.7% | -2739.7% | -9200.5% |
| Return on Equity | -269.6%-153.3pp | -116.3%-99.8pp | -16.6%-31.0pp | 14.5%+30.3pp | -15.8%+22.9pp | -38.7% | N/A | 219.6% | N/A | -401.8%-169.8pp | -232.0% |
| Return on Assets | -48.3%-4.7pp | -43.6%-29.0pp | -14.7%-27.1pp | 12.4%+22.8pp | -10.4%+3.4pp | -13.8%+16.4pp | -30.2%-47.0pp | 16.7%+92.4pp | -75.7%+3.2pp | -78.8% | N/A |
| Current Ratio | 3.18-0.1x | 3.32-5.3x | 8.59 | N/A | 9.12+3.3x | 5.82+3.9x | 1.93-1.0x | 2.90+1.3x | 1.63-3.8x | 5.41 | N/A |
| Debt-to-Equity | 0.50+0.3x | 0.15+0.1x | 0.07+0.1x | 0.000.0x | 0.000.0x | 0.00 | N/A | 12.12 | N/A | 4.10 | N/A |
| FCF Margin | -122.4% | -164.1% | -46.3%-80.1pp | 33.8% | -163.7% | N/A | N/A | 25.4% | -2482.9% | -3191.7% | -6214.7% |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin, FCF Margin.
Similar Companies
Where Cosciens Biopharma Ranks
Frequently Asked Questions
What is Cosciens Biopharma's annual revenue?
Cosciens Biopharma (CSCI) reported $7.5M in total revenue for fiscal year 2025. This represents a -21.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cosciens Biopharma's revenue growing?
Cosciens Biopharma (CSCI) revenue declined by 21.8% year-over-year, from $9.6M to $7.5M in fiscal year 2025.
Is Cosciens Biopharma profitable?
No, Cosciens Biopharma (CSCI) reported a net income of -$10.4M in fiscal year 2025.
How much debt does Cosciens Biopharma have?
As of fiscal year 2025, Cosciens Biopharma (CSCI) had $7.3M in cash and equivalents against $1.9M in long-term debt.
What is Cosciens Biopharma's return on equity (ROE)?
Cosciens Biopharma (CSCI) has a return on equity of -269.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Cosciens Biopharma's free cash flow?
Cosciens Biopharma (CSCI) recorded an outflow of $9.2M in free cash flow during fiscal year 2025. This represents a 41.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cosciens Biopharma's operating cash flow?
Cosciens Biopharma (CSCI) recorded an outflow of $8.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Cosciens Biopharma's total assets?
Cosciens Biopharma (CSCI) had $21.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Cosciens Biopharma's capital expenditures?
Cosciens Biopharma (CSCI) invested $706K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Cosciens Biopharma's current ratio?
Cosciens Biopharma (CSCI) had a current ratio of 3.18 as of fiscal year 2025, which is generally considered healthy.
What is Cosciens Biopharma's debt-to-equity ratio?
Cosciens Biopharma (CSCI) had a debt-to-equity ratio of 0.50 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cosciens Biopharma's return on assets (ROA)?
Cosciens Biopharma (CSCI) had a return on assets of -48.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Cosciens Biopharma's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Cosciens Biopharma (CSCI) held $7.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $8.5M over that year. Dividing the one by the other, the reported balance equals about 10 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Cosciens Biopharma's Piotroski F-Score?
Cosciens Biopharma (CSCI) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cosciens Biopharma's earnings high quality?
Cosciens Biopharma (CSCI) reported a net loss of $10.4M while operations used $8.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Cosciens Biopharma?
Cosciens Biopharma (CSCI) scores 36 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.